Streamline Health Solutions (STRM) 10-Q 17 Dec 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Oct. 31, 2013	Dec. 12, 2013
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'STREAMLINE HEALTH SOLUTIONS INC.	'
Entity Central Index Key	'0001008586	'
Document Type	'10-Q	'
Document Period End Date	31-Oct-13	'
Amendment Flag	'false	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Current Fiscal Year End Date	'--01-31	'
Entity Filer Category	'Non-accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	17,392,444

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Oct. 31, 2013	Jan. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$4,263,991	$7,500,256
Accounts receivable, net of allowance for doubtful accounts of $109,000 and $134,000, respectively	6,885,405	8,685,017
Contract receivables	1,387,147	1,481,819
Prepaid hardware and third party software for future delivery	25,463	22,777
Prepaid client maintenance contracts	1,230,073	1,080,330
Other prepaid assets	963,771	997,024
Other current assets	76,544	110,555
Total current assets	14,832,394	19,877,778
Property and equipment:	'	'
Computer equipment	3,496,270	3,420,452
Computer software	2,205,941	2,196,236
Office furniture, fixtures and equipment	886,664	843,274
Leasehold improvements	697,570	697,570
Property and equipment, gross	7,286,445	7,157,532
Accumulated depreciation and amortization	-6,446,291	-5,958,727
Property and equipment, net	840,154	1,198,805
Contract receivables, less current portion	87,105	126,626
Capitalized software development costs, net of accumulated amortization of $19,551,000 and $17,465,000, respectively	11,777,539	12,816,486
Intangible assets, net	12,044,903	8,188,131
Deferred financing costs, net	243,622	541,740
Goodwill	12,344,199	12,133,304
Other	543,087	383,708
Total non-current assets	37,880,609	35,388,800
Total assets	52,713,003	55,266,578
Current liabilities:	'	'
Accounts payable	1,601,279	1,495,913
Accrued compensation	1,301,613	2,088,850
Accrued other expenses	1,838,952	1,325,039
Current portion of long-term debt	12,750,000	1,250,000
Deferred revenues	7,126,543	9,810,442
Current portion of consideration for earn-out	4,560,000	1,319,559
Current portion of deferred tax liability	0	35,619
Total current liabilities	29,178,387	17,325,422
Non-current liabilities:	'	'
Term loans	0	12,437,501
Warrants liability	6,393,435	3,649,349
Contingent Consideration for Earn Out Non Current	900,000	0
Royalty Guarantees, Commitments, Amount	2,225,000	0
Lease incentive liability, less current portion	81,228	99,579
Deferred income tax liability, less current portion	792,506	529,709
Total non-current liabilities	10,392,169	16,716,138
Total liabilities	39,570,556	34,041,560
Series A 0% Convertible Redeemable Preferred Stock, $.01 par value per share, $9,749,985 redemption value, 4,000,000 shares authorized, 3,249,995 shares issued and outstanding, net of unamortized preferred stock discount of $2,400,475 and $4,234,269, respectively	7,578,465	7,765,716
Stockholders’ equity:	'	'
Common stock, $.01 par value per share, 25,000,000 shares authorized; 13,922,834 and 12,643,620 shares issued and outstanding, respectively	139,228	126,436
Additional paid in capital	51,040,745	49,178,389
Accumulated deficit	-45,615,991	-35,845,523
Total stockholders’ equity	5,563,982	13,459,302
Total liability and stockholders' equity	52,713,003	55,266,578
Convertible Redeemable Preferred Stock | Series A	'	'
Stockholders’ equity:	'	'
Convertible redeemable preferred stock, $.01 par value per share, 1,000,000 shares authorized, no shares issued	$0	$0

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	9 Months Ended	12 Months Ended
	Oct. 31, 2013	Jan. 31, 2013
Allowance for doubtful accounts	$134,000	$134,000
Accumulated amortization of capitalized software development costs	18,861,000	17,465,000
Common stock, par value (USD per share)	$0.01	$0.01
Common stock, shares authorized	25,000,000	25,000,000
Common stock, shares issued	13,039,619	13,039,619
Common stock, shares outstanding	12,643,620	12,643,620
Series A Preferred Stock	'	'
Preferred stock dividend rate	0.00%	0.00%
Convertible redeemable preferred stock, par value (USD per share)	$0.01	$0.01
Convertible redeemable preferred stock, redemption value	11,999,985	11,999,985
Convertible redeemable preferred stock, shares authorized	4,000,000	4,000,000
Convertible redeemable preferred stock, shares issued	3,999,995	3,999,995
Convertible redeemable preferred stock, shares outstanding	3,999,995	3,999,995
Unamortized preferred stock discount	$4,034,470	$4,234,269
Preferred stock, shares issued	750,000	'
Convertible Redeemable Preferred Stock | Series A	'	'
Preferred stock, par value (USD per share)	$0.01	$0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended
	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2013	Oct. 31, 2012
Revenues:	'	'	'	'
Systems sales	$347,532	$290,294	$2,905,846	$719,495
Professional services	966,962	1,089,814	2,925,553	3,153,672
Maintenance and support	3,523,551	3,148,442	10,524,595	7,797,263
Software as a service	1,893,489	2,005,813	5,622,237	5,358,120
Total revenues	6,731,534	6,534,363	21,978,231	17,028,550
Operating expenses:	'	'	'	'
Cost of systems sales	611,887	717,901	1,911,609	1,936,761
Cost of professional services	1,262,559	854,997	3,503,765	1,910,951
Cost of maintenance and support	739,887	918,750	2,519,952	2,349,745
Cost of software as a service	520,062	550,875	1,613,217	1,849,962
Selling, general and administrative	3,373,230	2,926,830	10,362,246	6,800,794
Research and development	1,370,178	866,659	3,627,336	1,833,865
Total operating expenses	7,877,803	6,836,012	23,538,125	16,682,078
Operating income (loss)	-1,146,269	-301,649	-1,559,894	346,472
Other income (expense):	'	'	'	'
Interest expense	-580,390	-895,142	-1,734,763	-1,494,161
Miscellaneous income (expenses)	-4,510,439	43,549	-6,316,867	55,805
Loss before income taxes	-6,237,098	-1,153,242	-9,611,524	-1,091,884
Income tax benefit (expense)	4,680	3,552,879	-158,944	3,519,879
Net earnings (loss)	-6,232,418	2,399,637	-9,770,468	2,427,995
Less: deemed dividends on Series A Preferred Shares	-374,162	-139,133	-731,309	-139,133
Net earnings (loss) attributable to common shareholders	($6,606,580)	$2,260,504	($10,501,777)	$2,288,862
Basic net earnings (loss) per common share (in dollars per share)	($0.50)	$0.18	($0.82)	$0.20
Number of shares used in basic per common share computation	13,257,943	12,393,352	12,884,711	11,346,428
Diluted net earnings (loss) per common share (in dollars per share)	($0.50)	$0.15	($0.82)	$0.18
Number of shares used in diluted per common share computation	13,257,943	15,365,238	12,884,711	12,417,256

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended
	Oct. 31, 2013	Oct. 31, 2012
Operating activities:	'	'
Net earnings (loss)	($9,770,468)	$2,427,995
Adjustments to reconcile net earnings (loss) to net cash provided by operating activities:	'	'
Depreciation	490,043	546,354
Amortization of intangible assets	2,086,885	1,928,038
Amortization of intangible assets	946,228	256,976
Amortization of other deferred costs	296,942	227,881
Valuation adjustment for warrants liability	2,082,789	0
Deferred tax expense	150,634	-3,564,612
Valuation adjustment for contingent earn-out	4,140,441	86,839
Proceeds from Convertible Debt	0	56,682
Share-based compensation expense	1,203,919	645,407
Changes in assets and liabilities, net of assets acquired:	'	'
Accounts and contract receivables	2,509,842	-1,351,935
Other assets	-627,883	-482,785
Accounts payable	87,014	-137,107
Accrued expenses	-150,206	947,630
Deferred revenues	-2,683,899	881,677
Net cash provided by operating activities	762,281	2,469,040
Investing activities:	'	'
Purchases of property and equipment	-106,392	-546,061
Capitalization of software development costs	-1,047,938	-1,571,420
Payments to Acquire Businesses, Net of Cash Acquired	-3,000,000	-12,161,634
Net cash used in investing activities	-4,154,330	-14,279,115
Proceeds from Issuance of Long-term Debt	0	9,880,000
Financing activities:	'	'
Principal repayments on term loans	-937,501	0
Payments of Financing Costs	0	-1,246,107
Proceeds from Issuance of Private Placement	0	12,000,000
Payment of Success Fees in Financing Activities	0	-700,000
Proceeds from exercise of stock options and stock purchase plan	1,093,285	161,823
Net cash provided by financing activities	155,784	20,095,716
(Decrease) increase in cash and cash equivalents	-3,236,265	8,285,641
Cash and cash equivalents at beginning of period	7,500,256	2,243,054
Cash and cash equivalents at end of period	$4,263,991	$10,528,695

Basis_of_Presentation

Basis of Presentation	9 Months Ended
	Oct. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
BASIS OF PRESENTATION	'
	BASIS OF PRESENTATION
	The accompanying unaudited Condensed Consolidated Financial Statements have been prepared by Streamline Health Solutions, Inc. (the "Company"), pursuant to the rules and regulations applicable to quarterly reports on Form 10-Q of the U. S. Securities and Exchange Commission. Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures made are adequate to make the information not misleading. In the opinion of our management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the Condensed Consolidated Financial Statements have been included. These Condensed Consolidated Financial Statements should be read in conjunction with the financial statements and notes thereto included in our most recent annual report on Form 10-K, Commission File Number 0-28132. Operating results for the three and nine months ended October 31, 2013 are not necessarily indicative of the results that may be expected for the fiscal year ending January 31, 2014.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
	Oct. 31, 2013
Accounting Policies [Abstract]	'
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	The Company's significant accounting policies are presented in “Note B – Significant Accounting Policies” in the fiscal year 2012 Annual Report on Form 10-K. Users of financial information for interim periods are encouraged to refer to the footnotes contained in the Annual Report on Form 10-K when reviewing interim financial results.
	Use of Estimates
	The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.
	Fair Value of Financial Instruments
	The FASB’s authoritative guidance on fair value measurements establishes a framework for measuring fair value, and expands disclosure about fair value measurements. This guidance enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. Under this guidance, assets and liabilities carried at fair value must be classified and disclosed in one of the following three categories:
	Level 1: Quoted market prices in active markets for identical assets or liabilities.
	Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data.
	Level 3: Unobservable inputs that are not corroborated by market data.
	The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value based on the short-term maturity of these instruments. Cash and cash equivalents are classified as Level 1. The carrying amount of the Company’s long-term debt approximates fair value since the interest rates being paid on the amounts approximate the market interest rate. Long-term debt is classified as Level 2. The initial fair value of contingent consideration for earn-out and warrants liability is determined by management with the assistance of an independent third party valuation specialist. The Company used a Black-Scholes option pricing model to estimate the fair value of the contingent consideration for earn-out and warrants liability. The contingent consideration for earn-out and warrants liability are classified as Level 3.
	Revenue Recognition
	The Company derives revenue from the sale of internally developed software either by licensing or by software as a service ("SaaS"), through the direct sales force or through third-party resellers. Licensed, locally-installed, clients utilize the Company’s support and maintenance services for a separate fee, whereas SaaS fees include support and maintenance. The Company also derives revenue from professional services that support the implementation, configuration, training, and optimization of the applications. Additional revenues are also derived from reselling third-party software and hardware components.
	The Company recognizes revenue in accordance with ASC 985-605, Software-Revenue Recognition and ASC 605-25 Revenue Recognition — Multiple-element arrangements. The Company commences revenue recognition when the following criteria all have been met:
	•	Persuasive evidence of an arrangement exists,
	•	Delivery has occurred or services have been rendered,
	•	The arrangement fees are fixed or determinable, and
	•	Collection is considered probable
	If the Company determines that any of the above criteria have not been met, the Company will defer recognition of the revenue until all the criteria have been met. Maintenance and support and SaaS agreements entered into are generally non-cancelable, or contain significant penalties for early cancellation, although clients typically have the right to terminate their contracts for cause if the Company fails to perform material obligations. However, if non-standard acceptance periods or non-standard performance criteria, cancellation or right of refund terms are required, revenue is recognized upon the satisfaction of such criteria, as applicable.
	Revenues from resellers are recognized gross of royalty payments to resellers.
	Multiple Element Arrangements
	On February 1, 2011, the Company adopted Accounting Standards Update No. 2009-13, Revenue Recognition (Topic 605), “Multiple-Deliverable Revenue Arrangements — a consensus of the FASB Emerging Issues Task Force” (“ASU 2009-13”) on a prospective basis. ASU 2009-13 amended the accounting standards for revenue recognition for multiple deliverable revenue arrangements to:
	•	Provide updated guidance on how deliverables of an arrangement are separated, and how consideration is allocated;
	•	Eliminate the residual method and require entities to allocate revenue using the relative selling price method and;
	•	Require entities to allocate revenue to an arrangement using the estimated selling price (“ESP”) of deliverables if it does not have vendor specific objective evidence (“VSOE”) or third party evidence (“TPE”) of selling price.
	Terms used in evaluation are as follows:
	•	VSOE — the price at which an element is sold as a separate stand-alone transaction
	•	TPE — the price of an element, charged by another company that is largely interchangeable in any particular transaction
	•	ESP — the Company’s best estimate of the selling price of an element of the transaction
	The Company follows accounting guidance for revenue recognition of multiple-element arrangements to determine whether such arrangements contain more than one unit of accounting. Multiple-element arrangements require the delivery or performance of multiple solutions, services and/or rights to use assets. To qualify as a separate unit of accounting, the delivered item must have value to the client on a stand-alone basis. Stand-alone value to a client is defined in the guidance as those that can be sold separately by any vendor or the client could resell the item on a stand-alone basis. Additionally, if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item or items must be considered probable and substantially in the control of the vendor.
	The Company has a defined pricing methodology for all elements of the arrangement and proper review of pricing to ensure adherence to Company policies. Pricing decisions include cross-functional teams of senior management, which uses market conditions, expected contribution margin, size of the client’s organization, and pricing history for similar solutions when establishing the selling price.
	Software as a Service
	The Company uses ESP to determine the value for a software as a service arrangement as the Company cannot establish VSOE and TPE is not a practical alternative due to differences in functionality from the Company's competitors. Similar to proprietary license sales, pricing decisions rely on the relative size of the client purchasing the solution, and include calculating the equivalent value of maintenance and support on a present value basis over the term of the initial agreement period. Typically revenue recognition commences upon client go-live on the system, and is recognized ratably over the contract term. The software portion of SaaS for Health Information Management ("HIM") products does not need material modification to achieve its contracted function. The software portion of SaaS for the Company's Patient Financial Services ("PFS") products require material customization and setup processes to achieve their contracted function.
	System Sales
	The Company uses the residual method to determine fair value for proprietary software licenses sold in a multi-element arrangement. Under the residual method, the Company allocates the total value of the arrangement first to the undelivered elements based on their VSOE and allocates the remainder to the proprietary software license fees.
	Typically pricing decisions for proprietary software rely on the relative size and complexity of the client purchasing the solution. Third party components are resold at prices based on a cost plus margin analysis. The proprietary software and third party components do not need any significant modification to achieve its intended use. When these revenues meet all criteria for revenue recognition, and are determined to be separate units of accounting, revenue is recognized. Typically this is upon shipment of components or electronic download of software. Proprietary licenses are perpetual in nature, and license fees do not include rights to version upgrades, fixes or service packs.
	Maintenance and Support Services
	The maintenance and support components are not essential to the functionality of the software, and clients renew maintenance contracts separately from software purchases at renewal rates materially similar to the initial rate charged for maintenance on the initial purchase of software. The Company uses VSOE of fair value to determine fair value of maintenance and support services. Rates are set based on market rates for these types of services, and the Company’s rates are comparable to rates charged by its competitors, which is based on the knowledge of the marketplace by senior management. Generally, maintenance and support is calculated as a percentage of the list price of the proprietary license being purchased by a client. Clients have the option of purchasing additional annual maintenance service renewals each year for which rates are not materially different from the initial rate, but typically include a nominal rate increase based on the consumer price index. Annual maintenance and support agreements entitle clients to technology support, upgrades, bug fixes and service packs.
	Term Licenses
	The Company cannot establish VSOE fair value of the undelivered element in term license arrangements.  However, as the only undelivered element is post-contract customer support, the entire fee is recognized ratably over the contract term.  Typically revenue recognition commences once the client goes live on the system.  Similar to proprietary license sales, pricing decisions rely on the relative size of the client purchasing the solution. The software portion of the Company's Collabra (“Coding”) products generally do not require material modification to achieve their contracted function.
	Professional Services
	Professional services components that are not essential to the functionality of the software, from time to time, are sold separately by the Company. Similar services are sold by other vendors, and clients can elect to perform similar services in-house. When professional services revenues are a separate unit of accounting, revenues are recognized as the services are performed.
	Professional services components that are essential to the functionality of the software, and are not considered a separate unit of accounting, are recognized in revenue ratably over the life of the client, which approximates the duration of the initial contract term. The Company defers the associated direct costs for salaries and benefits expense for professional services contracts. As of October 31, 2013 and January 31, 2013, the Company had deferred costs of approximately $368,000 and $201,000, respectively. These deferred costs will be amortized over the identical term as the associated SaaS revenues. Accumulated amortization of these costs was approximately $85,000 and $35,000 as of October 31, 2013 and January 31, 2013, respectively.
	The Company uses VSOE of fair value based on the hourly rate charged when services are sold separately, to determine fair value of professional services. The Company typically sells professional services on a fixed fee basis. The Company monitors projects to assure that the expected and historical rate earned remains within a reasonable range to the established selling price.
	Severances
	From time to time, the Company will enter into termination agreements with associates that may include supplemental cash payments, as well as contributions to health and other benefits for a specific time period subsequent to termination. For the three months ended October 31, 2013 and 2012 , the Company incurred approximately zero and $207,000 in severance expenses, respectively, and $380,000 and $277,000 for the nine months ended October 31, 2013 and 2012, respectively. At October 31, 2013 and January 31, 2013, the Company had accrued for $13,000 and $548,000 in severances, respectively.
	Equity Awards
	The Company accounts for share-based payments based on the grant-date fair value of the awards with compensation cost recognized as expense over the requisite vesting period. The Company incurred total compensation expense related to stock-based awards of $378,000 and $245,000 for the three months ended October 31, 2013 and 2012, respectively, and $1,204,000 and $645,000 for the nine months ended October 31, 2013 and 2012, respectively.
	The fair value of the stock options granted have been estimated at the date of grant using a Black-Scholes option pricing model. The option pricing model inputs assumptions such as expected term, expected volatility, and risk-free interest rate impact the fair value estimate. Further, the forfeiture rate impacts the amount of aggregate compensation. These assumptions are subjective and are generally derived from external (such as, risk-free rate of interest) and historical data (such as, volatility factor, expected term, and forfeiture rates). Future grants of equity awards accounted for as stock-based compensation could have a material impact on reported expenses depending upon the number, value and vesting period of future awards.
	The Company issues restricted stock awards in the form of Company common stock. The fair value of these awards is based on the market close price per share on the day of grant. The Company expenses the compensation cost of these awards as the restriction period lapses, which is typically a one-year service period to the Company.
	Income Taxes
	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and for tax credit and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In assessing net deferred tax assets, the Company considers whether it is more likely than not that some or all of the deferred tax assets will not be realized. The Company establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.
	The Company provides for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether certain tax positions are more likely than not to be sustained upon examination by tax authorities. As of October 31, 2013, the Company believes it has appropriately accounted for any uncertain tax positions. As part of the Meta acquisition (discussed at Note C, below), the Company assumed a current liability for an uncertain tax position, and expects to settle this amount in fiscal 2013. The Company has a $152,000 reserve for uncertain tax positions and corresponding interest and penalties as of both October 31, 2013 and January 31, 2013, respectively.
	Net Earnings (Loss) Per Common Share
	The Company presents basic and diluted earnings per share (“EPS”) data for its common stock. Basic EPS is calculated by dividing the net income (loss) attributable to shareholders of the Company by the weighted average number of shares of common stock outstanding during the period. Diluted EPS is determined by adjusting the profit or loss attributable to shareholders and the weighted average number of shares of common stock outstanding adjusted for the effects of all dilutive potential common shares comprised of options granted, unvested restricted stocks, warrants and convertible preferred stock. Potential common stock equivalents that have been issued by the Company related to outstanding stock options, unvested restricted stock and warrants are determined using the treasury stock method, while potential common shares related to Series A Convertible Preferred Stock are determined using the “if converted” method.
	The Company's unvested restricted stock awards and Series A Convertible Preferred stock are considered participating securities under ASC 260, “Earnings Per Share”, which means the security may participate in undistributed earnings with common stock. The Company's unvested restricted stock awards are considered participating securities because they entitle holders to non-forfeitable rights to dividends or dividend equivalents during the vesting term. The holders of the Series A Preferred Stock would be entitled to share in dividends, on an as-converted basis, if the holders of common stock were to receive dividends, other than dividends in the form of common stock. In accordance with ASC 260, a company is required to use the two-class method when computing EPS when a company has a security that qualifies as a “participating security.” The two-class method is an earnings allocation formula that determines EPS for each class of common stock and participating security according to dividends declared (or accumulated) and participation rights in undistributed earnings. In determining the amount of net earnings to allocate to common stock holders, earnings are allocated to both common and participating securities based on their respective weighted-average shares outstanding for the period. Diluted EPS for the Company's common stock is computed using the more dilutive of the two-class method or the if-converted method.
	In accordance with ASC 260, securities are deemed to not be participating in losses if there is no obligation to fund such losses. For the three and nine months ended October 31, 2013, the unvested restricted stock awards and the Series A Preferred Stock were not deemed to be participating since there was a net loss from operations. For the three and nine months ended October 31, 2013, the effect of unvested restricted stock to the earnings per share calculation was immaterial. As of October 31, 2013, there were 3,249,995 shares of preferred stock outstanding, each share is convertible into one share of the Company's common stock. For the three and nine months ended October 31, 2013, the Series A Convertible Preferred Stock would have an anti-dilutive effect if included in diluted EPS and therefore, was not included in the calculation. As of October 31, 2013 and January 31, 2013, there were 29,698 and 137,327, respectively, unvested restricted shares of common stock outstanding. The unvested restricted shares at October 31, 2013 and January 31, 2013 were excluded from the calculation as their effect would have been antidilutive.
	The following is the calculation of the basic and diluted net earnings (loss) per share of common stock:
		Three Months Ended
		31-Oct-13			31-Oct-12
	Net earnings (loss)	$	(6,232,418	)	$	2,399,637
	Less: deemed dividends on Series A Preferred Stock	(374,162		)	(139,133		)
	Net earnings (loss) attributable to common shareholders	$	(6,606,580	)	$	2,260,504
	Weighted average shares outstanding used in basic per common share computations	13,257,943			12,393,352
Stock options and restricted stock	—			2,971,886
Number of shares used in diluted per common share computation	13,257,943			15,365,238
Basic net earnings (loss) per share of common stock	$	(0.50	)	$	0.18
Diluted net earnings (loss) per share of common stock	$	(0.50	)	$	0.15
	Nine Months Ended
	31-Oct-13			31-Oct-12
Net earnings (loss)	$	(9,770,468	)	$	2,427,995
Less: deemed dividends on Series A Preferred Stock	(731,309		)	(139,133		)
Net earnings (loss) attributable to common shareholders	$	(10,501,777	)	$	2,288,862
Weighted average shares outstanding used in basic per common share computations	12,884,711			11,346,428
Stock options and restricted stock	—			1,070,828
Number of shares used in diluted per common share computation	12,884,711			12,417,256
Basic net earnings (loss) per share of common stock	$	(0.82	)	$	0.2
Diluted net earnings (loss) per share of common stock	$	(0.82	)	$	0.18
Diluted net earnings (loss) per share exclude the effect of 2,562,317 and 2,585,079 outstanding stock options for the three and nine months ended October 31, 2013 and 2012, respectively. The inclusion of these shares would be anti-dilutive. For the nine months ended October 31, 2013, the outstanding common stock warrants of 1,400,000 would have an anti-dilutive effect if included in diluted EPS and therefore, were not included in the calculation. There were no outstanding warrants as of October 31, 2012.
Recent Accounting Pronouncements
In February 2013, the Financial Accounting Standards Board ("FASB") issued an accounting standard update relating to improving the reporting of reclassifications out of accumulated other comprehensive income. The update would require an entity to report the effect of significant reclassifications out of accumulated other comprehensive income on the respective line items in net income if the amount being reclassified is required under GAAP to be reclassified in its entirety to net income. For other amounts that are not required under GAAP to be reclassified in their entirety to net income in the same reporting period, an entity is required to cross-reference other disclosures required under GAAP that provide additional detail about those amounts. The update is effective for reporting periods beginning after December 15, 2012. This standard did not have a material effect on the Company's consolidated financial position, results of operations, or cash flows.
In July 2013, FASB issued an accounting standard update relating to the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. This update amends existing GAAP that required in certain cases, an unrecognized tax benefit, or portion of an unrecognized tax benefit, to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward when such items exist in the same taxing jurisdiction. The amendments in this update are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. Early adoption is permitted. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date, and retrospective application is permitted. We do not expect any impact from this update on our financial statements.

Acquisitions

Acquisitions	9 Months Ended
	Oct. 31, 2013
Business Combinations [Abstract]	'
ACQUISITIONS	'
	ACQUISITIONS
	On December 7, 2011, the Company completed the acquisition of substantially all of the assets of Interpoint Partners, LLC (“Interpoint”). This acquisition expanded the Company’s product offering into business intelligence and revenue cycle performance management. The purchase agreement included a contingent earn-out provision, which has a settlement value of $5,460,000 at October 31, 2013 and had an estimated value of $1,320,000 at January 31, 2013. The purchase agreement provided that the contingent earn-out was to be paid in cash or an additional convertible subordinated note based on the acquired Interpoint operations financial performance for the 12-month period beginning July 1, 2012 and ending June 30, 2013.
	The Company has agreed to a final earn-out and will pay Interpoint an aggregate consideration consisting of $1,300,000 in cash, the issuance of 400,000 shares of Company common stock on January 1, 2014, and the issuance of an unsecured, subordinated three-year note in the amount of $900,000 that matures on November 1, 2016 and accrues interest on the unpaid principal amount actually outstanding at a per annum rate equal to 8%. The 400,000 shares were valued at October 31, 2013 based upon the closing price of the Company's common stock on that date.
	On August 16, 2012, the Company acquired substantially all of the outstanding stock of Meta Health Technology, Inc., a New York corporation (“Meta”). The Company paid a total purchase price of approximately $14,790,000, consisting of cash payment of $13,288,000 and the issuance of 393,086 shares of the Company's common stock at an agreed upon price of $4.07 per share. The fair value of the common stock at the date of issuance was $3.82.
	The acquisition of Meta represents the Company's on-going growth strategy, and is reflective of the solutions development process, which is led by the needs and requirements of clients and the marketplace in general. The Meta suite of solutions, when bundled with the Company's existing solutions, will help current and prospective clients better prepare for compliance with the ICD-10 transition. The Company believes that the integration of business analytics solutions with the coding solutions acquired in this transaction will position the Company to address the complicated issues of clinical analytics as clients prepare for the proposed changes in commercial and governmental payment models.
	The purchase price was subject to certain adjustments related principally to the delivered working capital level, which was settled in the third quarter of fiscal 2013, and/or indemnification provisions. As a result of the final working capital settlement, the Company has recorded in accounts receivable $378,000 as of October 31, 2013, with a corresponding reduction in goodwill. Under the acquisition method of accounting, the purchase price was allocated to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date as follows:
		August 16, 2012
	Assets purchased:
	Cash	$	1,126,000
	Accounts receivable	2,300,000
	Fixed assets	133,000
	Other assets	513,000
	Client relationships	4,464,000
	Internally developed software	3,646,000
	Trade name	1,588,000
	Supplier agreements	1,582,000
	Covenants not to compete	720,000
	Goodwill(1)	8,073,000
	Total assets purchased	$	24,145,000
	Liabilities assumed:
	Accounts payable and Accrued liabilities	1,259,000
	Deferred revenue obligation, net	3,494,000
	Deferred tax liability	4,602,000
	Net assets acquired	$	14,790,000
	Consideration:
	Company common stock	$	1,502,000
	Cash paid	13,288,000
	Total consideration	$	14,790,000
	_______________
	-1	Goodwill represents the excess of purchase price over the estimated fair value of net tangible and intangible assets acquired, which is not deductible for tax purposes.
	On October 25, 2013, the Company's wholly owned subsidiary, Streamline Health, Inc. ("Streamline"), entered into a Software License and Royalty Agreement (the “Royalty Agreement”) with Montefiore Medical Center ("Montefiore") pursuant to which it acquired an exclusive, worldwide 15-year license from Montefiore of its proprietary clinical analytics platform solution, Clinical Looking Glass ("CLG").  In addition, Montefiore assigned to Streamline the existing license agreement with a customer using CLG.  As consideration under the Royalty Agreement, Streamline paid Montefiore a one-time initial base royalty fee of $3,000,000, as well as on-going quarterly royalty amounts related to future sublicensing of CLG by Streamline.  Additionally, Streamline has committed that Montefiore will receive at least an additional $3,000,000 of on-going royalty payments within the first six and one-half years of the license term.
	The Montefiore agreements were accounted for as a business combination with the purchase price representing the $3,000,000 initial base royalty fee, plus the present value of the $3,000,000 on-going royalty payment commitment.The purchase price was allocated to the tangible and intangible assets acquired and liabilities assumed based on their estimate fair values as of the acquisition date as follows:
		October 25, 2013
	Assets purchased:
	License agreement	$	4,166,000
	Existing customer relationship	408,000
	Covenant not to compete	129,000
	Working capital	124,000
	Other assets	126,000
	Goodwill	272,000
	Total assets purchased	$	5,225,000
	Consideration:
	Cash paid	$	3,000,000
	Future royalty commitment	2,225,000
	Total consideration	$	5,225,000

Derivative_Liabilities

Derivative Liabilities	9 Months Ended
	Oct. 31, 2013
Other Liabilities Disclosure [Abstract]	'
DERIVATIVE LIABILITIES	'
	DERIVATIVE LIABILITIES
	In conjunction with the private placement investment, the Company issued common stock warrants exercisable for up to 1,200,000 shares of common stock at an exercise price of $3.99 per share. The warrants were initially classified in stockholders' equity as additional paid in capital at the allocated amount, net of allocated transaction costs, of approximately $1,425,000. Effective October 31, 2012, upon shareholder approval of anti-dilution provisions that reset the warrants' exercise price if a dilutive issuance occurs, the warrants were reclassified as non-current derivative liabilities. The fair value of the warrants was approximately $4,139,000 at October 31, 2012, with the difference between the fair value and carrying value recorded to additional paid in capital. Effective as of the reclassification as derivative liabilities, the warrants are re-valued at each reporting date, with changes in fair value recognized in earnings each reporting period as a credit or charge to miscellaneous income (expense). The fair value of the warrants at October 31, 2013 was approximately $6,393,000, with the increase in fair value since January 31, 2013 of approximately $2,083,000 recognized as miscellaneous expense in the condensed consolidated statements of operations. The estimated fair value of the warrant liabilities as of October 31, 2013 was computed using a Black-Scholes option pricing model simulations based on the following assumptions: annual volatility of 58.77%; risk-free rate of 0.97%, dividend yield of 0.0% and expected life of approximately 4.30 years. The model also included assumptions to account for anti-dilutive provisions within the warrant agreement.
	During the three months ended July 31 2013, the Company recorded an immaterial correction of an error regarding the valuation of its common stock warrants originated during the third quarter of fiscal 2012 in conjunction with its private placement investment. The Company concluded there was a cumulative $19,000 overstatement of the loss before income taxes on its condensed consolidated statement of operations for the fiscal year ended January 31, 2013, as previously reported. The aforementioned cumulative $19,000 overstatement has been recorded in the condensed consolidated statement of operations for the three months ended April 30, 2013. The January 31, 2013 condensed consolidated balance sheet, as previously reported, reflects a $51,000 overstatement of deferred financing costs, a cumulative $150,000 understatement of deemed dividends on Series A Preferred Stock, a $7,000 overstatement of the Series A preferred stock, and a $602,000 overstatement of additional paid in capital.
	During the three months ended October 31, 2013, the Company recorded an immaterial correction of an error regarding a $188,145 fiscal second quarter 2013 understatement of deemed dividends on its Series A Preferred Stock, with an offsetting understatement of additional paid in capital. These aforementioned condensed consolidated balance sheet adjustments have been recorded on the April 30, 2013 and October 31, 2013 condensed consolidated balance sheets, respectively. The Company concluded that the impact of the corrections was neither quantitatively nor qualitatively material to the prior fiscal year or the respective quarters ended in fiscal years 2012 and 2013.

Leases

Leases	9 Months Ended
	Oct. 31, 2013
Leases [Abstract]	'
LEASES	'
	LEASES
	The Company rents office and data center space and equipment under non-cancelable operating leases that expire at various times through fiscal year 2018. Future minimum lease payments under non-cancelable operating leases for the next five fiscal years are as follows:
		Facilities		Equipment		Fiscal Year Totals
	2013 (three months remaining)	$	237,000	$	39,000	$	276,000
	2014	717,000		151,000		868,000
	2015	322,000		109,000		431,000
	2016	162,000		2,000		164,000
	2017	167,000		—		167,000
	2018	85,000		—		85,000
	Total	$	1,690,000	$	301,000	$	1,991,000
	Rent and leasing expense for facilities and equipment was approximately $324,000 and $256,000 for the three months ended October 31, 2013 and 2012, respectively, and $877,000 and $702,000 for the nine months ended October 31, 2013 and 2012, respectively.

Debt

Debt	9 Months Ended
	Oct. 31, 2013
Debt Disclosure [Abstract]	'
DEBT	'
	DEBT
	Term Loan and Line of Credit
	On December 7, 2011, in conjunction with the Interpoint acquisition, the Company entered into a subordinated credit agreement with Fifth Third Bank in which the bank provided the Company with a $4,120,000 term loan, which was scheduled to mature on December 7, 2013, and a revolving line of credit, which was scheduled to mature on October 1, 2013.
	In conjunction with the Meta acquisition, on August 16, 2012, the Company amended the subordinated term loan and line of credit agreements with Fifth Third Bank, whereby Fifth Third Bank provided the Company with a $5,000,000 revolving line of credit, a $5,000,000 senior term loan and a $9,000,000 subordinated term loan, a portion of which was used to refinance the previously outstanding $4,120,000 subordinated term loan. Additionally, as part of the refinancing in August 2012, the Company mutually agreed to settle the success fee included in the previous subordinated term loan for $700,000. The difference between the $233,000 success fee accrued through the date of the amendment and the amount paid was recorded to deferred financing costs and is being amortized over the term of the amended loan. The Company paid a commitment fee in connection with the senior term loan of $75,000, which is included in deferred financing costs.
	The Company will be required to pay a success fee in accordance with the amended subordinated term loan, which is recorded in interest expense as accrued over the term of the loan. The success fee is due on the date the entire principal balance of the loan becomes due. The success fee is accrued in accordance with the terms of the loan in an amount necessary to provide the lender a 17% internal rate of return through the date the success fee becomes due.
	Effective December 13, 2013, the Company amended and restated the senior credit agreement and amended the subordinated credit agreement to increase the senior term loan to $8.5 million, extend the maturity of the senior term loan and the revolving line of credit to December 1, 2018 and December 1, 2015, respectively, reduce the interest rates and revise the financial covenants. The subordinated term loan matures on August 16, 2014. The loans are secured by substantially all of the Company's assets. The senior term loan principal balance is payable in monthly installments of approximately $101,000 commencing in January 2014, and will continue through the maturity date, with the full remaining unpaid principal balance due at maturity. The entire unpaid principal balance of the subordinated term loan is due at maturity. Borrowings under the senior term loan bear interest at a rate of LIBOR (0.17% at October 31, 2013) plus 4.75%, and borrowings under the subordinated term loan bear interest at 10% from August 16, 2012 and thereafter. Accrued and unpaid interest on the senior and subordinated term loans is due monthly through maturity. Borrowings under the revolving loan bear interest at a rate equal to LIBOR plus 3.50%. A commitment fee of 0.40% will be incurred on the unused revolving line of credit balance, and is payable monthly. As of October 31, 2013, the Company had no outstanding borrowings under the line of credit, and had accrued approximately $3,000 in unused balance commitment fees. The original proceeds of these loans were used to finance the cash portion of the acquisition purchase price and to cover any additional operating costs as a result of the Meta acquisition. A portion of the new senior term loan was used to refinance the previously outstanding $5,000,000 senior term loan. The Company will pay a commitment fee in connection with the new senior term loan of $100,000, which will be included in deferred financing costs.
	The significant covenants as set forth in the term loans and line of credit are as follows: (i) maintain adjusted EBITDA as of the end of the fiscal quarter on a trailing four fiscal quarter basis greater than: $5,000,000, (after consideration of certain acquisition and transaction costs), on January 31, 2014 and thereafter; (ii) maintain a fixed charge coverage ratio for the fiscal quarter ending January 31, 2013 and each fiscal quarter thereafter of not less than 1.20:1 calculated quarterly on a trailing four quarter basis thereafter; (iii) on a consolidated basis, maintain ratio of funded debt and senior funded debt to adjusted EBITDA as of the end of any fiscal quarter less than 3.5:1 and 2.5:1, respectively, calculated quarterly on a trailing four fiscal quarter basis beginning January 31, 2014. The Company is in compliance with all financial covenants applicable for the period ended October 31, 2013.
	Outstanding principal balances on long-term debt consisted of the following at:
		31-Oct-13		31-Jan-13
	Senior term loan	$	3,750,000	$	4,688,000
	Subordinated term loan	9,000,000		9,000,000
	Total	12,750,000		13,688,000
	Less: Current portion	12,750,000		1,250,000
	Non-current portion of long-term debt	$	—	$	12,438,000
	Future principal repayments of long-term debt consisted of the following at October 31, 2013:
		Payments Due by Period
		2013		2014
	Senior term loan	$	312,000	$	3,438,000
	Subordinated term loan	—		9,000,000
	Total principal repayments	$	312,000	$	12,438,000
	As discussed below, the Company issued an unsecured, subordinated three-year note, in the amount of $900,000 that matures on November 1, 2016 and accrues interest on the unpaid principal amount actually outstanding at a per annum rate equal to 8%. The promissory note was issued November 20, 2013 and has annual principal payments of $300,000 due on November 1, 2014, 2015 and 2016.
	Contingent Earn-Out Provision
	As part of the asset purchase, Interpoint is entitled to receive additional consideration contingent upon certain financial performance measurements during a one year earn-out period commencing July 1, 2012 and ending on June 30, 2013. The earn-out consideration is calculated as twice the recurring revenue for the earn-out period recognized by the acquired Interpoint operations from specific contracts defined in the asset purchase agreement, plus one times Interpoint revenue derived from the Company's customers, less $3,500,000. The earn-out consideration, if any, was due no later than July 31, 2013 in cash or through the issuance of a note with terms identical to the terms of the Convertible Note (which was converted on June 15, 2012, see "Note F - Debt" in the Notes to the Consolidated Financial Statements as part of the annual report on Form 10-K for the year ended January 31, 2013), except with respect to issue date, conversion date and prepayment date. The earn-out note restricts conversion or prepayment at any time prior to the one year anniversary of the issue date.
	The Company has agreed to a final earn-out and will pay Interpoint an aggregate consideration consisting of $1,300,000 in cash, the issuance of 400,000 shares of Company common stock on January 1, 2014, and the issuance of an unsecured, subordinated three-year note in the amount of $900,000 that matures on November 1, 2016 and accrues interest on the unpaid principal amount actually outstanding at a per annum rate equal to 8%. The 400,000 shares were valued at October 31, 2013 based upon the closing price of the Company's common stock on that date.
	As of October 31, 2013, the Company calculated the payment obligation in connection with the earn-out to be $5,460,000. As of January 31, 2013, the Company estimated the payment obligation to be $1,320,000. A cumulative change in value of the earn-out of $4,140,000 was recorded for the nine months ended October 31, 2013.

Income_Taxes

Income Taxes	9 Months Ended
	Oct. 31, 2013
Income Tax Disclosure [Abstract]	'
INCOME TAXES	'
	INCOME TAXES
	Income tax expense consists of federal, state and local tax provisions. For the nine months ended October 31, 2013 and 2012, the Company recorded federal tax provisions of $126,000 and $(3,565,000), respectively. For the nine months ended October 31, 2013 and 2012, the Company recorded state and local tax provisions of $33,000 and $30,000, respectively. Included in the second fiscal quarter 2013 tax expense is an expense of approximately $100,000 related to an immaterial error correction to the Company's January 31, 2013 net deferred tax liability related to the Interpoint acquisition. The Company concluded that the impact of the correction was not quantitatively and qualitatively material to the prior fiscal year end and the respective quarters ended in 2012 and 2013.

Subsequent_Events

Subsequent Events	9 Months Ended
	Oct. 31, 2013
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	SUBSEQUENT EVENTS
	On November 14, 2013, the Company announced that it has signed letters of intent to purchase two companies to augment its existing solutions across the entire patient experience.   The transactions are subject to the negotiation and execution of definitive acquisition agreements and the satisfaction of typical and customary closing conditions, including approval of the respective Boards of Directors of the Company and the targets and the targets’ shareholders. There can be no assurance as to whether or when the acquisitions may be completed or as to the actual terms of the acquisitions.
	The transaction expected to close first in the fiscal fourth quarter of 2013 would add patient access and scheduling capabilities.  The target company sells these solutions generally under a perpetual license model, however the Company intends to transition this revenue stream into a SaaS-based model much like the Company has done with that of Meta. For the twelve months ended June 30, 2013, total revenues were $3.9 million of which $3.2 million were recurring. The letter of intent provides that at closing the Company would pay approximately $6.5 million in cash for the target company.
	The second transaction, which is in the due diligence stage, is expected to close in the fiscal fourth quarter of 2013 or in the fiscal first quarter of 2014, and would add additional financial and operational analytics to the Company’s existing suite of solutions. The letter of intent provides that at closing the Company anticipates paying approximately $13.75 million in a combination of cash and shares of the Company’s common stock.

Stockholers_Equity_Notes

Stockholers Equity (Notes)	9 Months Ended
	Oct. 31, 2013
Equity [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	STOCKHOLDERS' EQUITY
	In October 2013, 750,000 shares of the Company's Series A Convertible Preferred Stock were converted into Common Stock. As a result, Series A Convertible Preferred Stock was reduced by $919,000, with the offsetting increase to Common Stock and Additional Paid in Capital. As of October 31, 2013, 3,249,995 shares of Series A Convertible Preferred Stock remained outstanding.
	On November 27, 2013, the Company closed its public offering of3,450,000shares of the Company’s common stock, including 450,000 shares issued in connection with an overallotment option exercised by the underwriters, at a price to the public of $6.50 per share. Aggregate net proceeds from the offering were approximately $20,345,000 after deducting $1,680,00 in underwriting discounts and commissions, and estimated offering expenses payable by the Company of approximately $400,000.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Oct. 31, 2013
Accounting Policies [Abstract]	'
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The FASB’s authoritative guidance on fair value measurements establishes a framework for measuring fair value, and expands disclosure about fair value measurements. This guidance enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. Under this guidance, assets and liabilities carried at fair value must be classified and disclosed in one of the following three categories:
	Level 1: Quoted market prices in active markets for identical assets or liabilities.
	Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data.
	Level 3: Unobservable inputs that are not corroborated by market data.
	The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value based on the short-term maturity of these instruments. Cash and cash equivalents are classified as Level 1. The carrying amount of the Company’s long-term debt approximates fair value since the interest rates being paid on the amounts approximate the market interest rate. Long-term debt is classified as Level 2. The initial fair value of contingent consideration for earn-out and warrants liability is determined by management with the assistance of an independent third party valuation specialist. The Company used a Black-Scholes option pricing model to estimate the fair value of the contingent consideration for earn-out and warrants liability. The contingent consideration for earn-out and warrants liability are classified as Level 3.
Revenue Recognition	'
	Revenue Recognition
	The Company derives revenue from the sale of internally developed software either by licensing or by software as a service ("SaaS"), through the direct sales force or through third-party resellers. Licensed, locally-installed, clients utilize the Company’s support and maintenance services for a separate fee, whereas SaaS fees include support and maintenance. The Company also derives revenue from professional services that support the implementation, configuration, training, and optimization of the applications. Additional revenues are also derived from reselling third-party software and hardware components.
	The Company recognizes revenue in accordance with ASC 985-605, Software-Revenue Recognition and ASC 605-25 Revenue Recognition — Multiple-element arrangements. The Company commences revenue recognition when the following criteria all have been met:
	•	Persuasive evidence of an arrangement exists,
	•	Delivery has occurred or services have been rendered,
	•	The arrangement fees are fixed or determinable, and
	•	Collection is considered probable
	If the Company determines that any of the above criteria have not been met, the Company will defer recognition of the revenue until all the criteria have been met. Maintenance and support and SaaS agreements entered into are generally non-cancelable, or contain significant penalties for early cancellation, although clients typically have the right to terminate their contracts for cause if the Company fails to perform material obligations. However, if non-standard acceptance periods or non-standard performance criteria, cancellation or right of refund terms are required, revenue is recognized upon the satisfaction of such criteria, as applicable.
	Revenues from resellers are recognized gross of royalty payments to resellers.
	Multiple Element Arrangements
	On February 1, 2011, the Company adopted Accounting Standards Update No. 2009-13, Revenue Recognition (Topic 605), “Multiple-Deliverable Revenue Arrangements — a consensus of the FASB Emerging Issues Task Force” (“ASU 2009-13”) on a prospective basis. ASU 2009-13 amended the accounting standards for revenue recognition for multiple deliverable revenue arrangements to:
	•	Provide updated guidance on how deliverables of an arrangement are separated, and how consideration is allocated;
	•	Eliminate the residual method and require entities to allocate revenue using the relative selling price method and;
	•	Require entities to allocate revenue to an arrangement using the estimated selling price (“ESP”) of deliverables if it does not have vendor specific objective evidence (“VSOE”) or third party evidence (“TPE”) of selling price.
	Terms used in evaluation are as follows:
	•	VSOE — the price at which an element is sold as a separate stand-alone transaction
	•	TPE — the price of an element, charged by another company that is largely interchangeable in any particular transaction
	•	ESP — the Company’s best estimate of the selling price of an element of the transaction
	The Company follows accounting guidance for revenue recognition of multiple-element arrangements to determine whether such arrangements contain more than one unit of accounting. Multiple-element arrangements require the delivery or performance of multiple solutions, services and/or rights to use assets. To qualify as a separate unit of accounting, the delivered item must have value to the client on a stand-alone basis. Stand-alone value to a client is defined in the guidance as those that can be sold separately by any vendor or the client could resell the item on a stand-alone basis. Additionally, if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item or items must be considered probable and substantially in the control of the vendor.
	The Company has a defined pricing methodology for all elements of the arrangement and proper review of pricing to ensure adherence to Company policies. Pricing decisions include cross-functional teams of senior management, which uses market conditions, expected contribution margin, size of the client’s organization, and pricing history for similar solutions when establishing the selling price.
	Software as a Service
	The Company uses ESP to determine the value for a software as a service arrangement as the Company cannot establish VSOE and TPE is not a practical alternative due to differences in functionality from the Company's competitors. Similar to proprietary license sales, pricing decisions rely on the relative size of the client purchasing the solution, and include calculating the equivalent value of maintenance and support on a present value basis over the term of the initial agreement period. Typically revenue recognition commences upon client go-live on the system, and is recognized ratably over the contract term. The software portion of SaaS for Health Information Management ("HIM") products does not need material modification to achieve its contracted function. The software portion of SaaS for the Company's Patient Financial Services ("PFS") products require material customization and setup processes to achieve their contracted function.
	System Sales
	The Company uses the residual method to determine fair value for proprietary software licenses sold in a multi-element arrangement. Under the residual method, the Company allocates the total value of the arrangement first to the undelivered elements based on their VSOE and allocates the remainder to the proprietary software license fees.
	Typically pricing decisions for proprietary software rely on the relative size and complexity of the client purchasing the solution. Third party components are resold at prices based on a cost plus margin analysis. The proprietary software and third party components do not need any significant modification to achieve its intended use. When these revenues meet all criteria for revenue recognition, and are determined to be separate units of accounting, revenue is recognized. Typically this is upon shipment of components or electronic download of software. Proprietary licenses are perpetual in nature, and license fees do not include rights to version upgrades, fixes or service packs.
	Maintenance and Support Services
	The maintenance and support components are not essential to the functionality of the software, and clients renew maintenance contracts separately from software purchases at renewal rates materially similar to the initial rate charged for maintenance on the initial purchase of software. The Company uses VSOE of fair value to determine fair value of maintenance and support services. Rates are set based on market rates for these types of services, and the Company’s rates are comparable to rates charged by its competitors, which is based on the knowledge of the marketplace by senior management. Generally, maintenance and support is calculated as a percentage of the list price of the proprietary license being purchased by a client. Clients have the option of purchasing additional annual maintenance service renewals each year for which rates are not materially different from the initial rate, but typically include a nominal rate increase based on the consumer price index. Annual maintenance and support agreements entitle clients to technology support, upgrades, bug fixes and service packs.
	Term Licenses
	The Company cannot establish VSOE fair value of the undelivered element in term license arrangements.  However, as the only undelivered element is post-contract customer support, the entire fee is recognized ratably over the contract term.  Typically revenue recognition commences once the client goes live on the system.  Similar to proprietary license sales, pricing decisions rely on the relative size of the client purchasing the solution. The software portion of the Company's Collabra (“Coding”) products generally do not require material modification to achieve their contracted function.
	Professional Services
	Professional services components that are not essential to the functionality of the software, from time to time, are sold separately by the Company. Similar services are sold by other vendors, and clients can elect to perform similar services in-house. When professional services revenues are a separate unit of accounting, revenues are recognized as the services are performed.
	Professional services components that are essential to the functionality of the software, and are not considered a separate unit of accounting, are recognized in revenue ratably over the life of the client, which approximates the duration of the initial contract term. The Company defers the associated direct costs for salaries and benefits expense for professional services contracts. As of October 31, 2013 and January 31, 2013, the Company had deferred costs of approximately $368,000 and $201,000, respectively. These deferred costs will be amortized over the identical term as the associated SaaS revenues. Accumulated amortization of these costs was approximately $85,000 and $35,000 as of October 31, 2013 and January 31, 2013, respectively.
	The Company uses VSOE of fair value based on the hourly rate charged when services are sold separately, to determine fair value of professional services. The Company typically sells professional services on a fixed fee basis. The Company monitors projects to assure that the expected and historical rate earned remains within a reasonable range to the established selling price.
Severances	'
	Severances
	From time to time, the Company will enter into termination agreements with associates that may include supplemental cash payments, as well as contributions to health and other benefits for a specific time period subsequent to termination. For the three months ended October 31, 2013 and 2012 , the Company incurred approximately zero and $207,000 in severance expenses, respectively, and $380,000 and $277,000 for the nine months ended October 31, 2013 and 2012, respectively. At October 31, 2013 and January 31, 2013, the Company had accrued for $13,000 and $548,000 in severances, respectively.
Equity Awards	'
	Equity Awards
	The Company accounts for share-based payments based on the grant-date fair value of the awards with compensation cost recognized as expense over the requisite vesting period. The Company incurred total compensation expense related to stock-based awards of $378,000 and $245,000 for the three months ended October 31, 2013 and 2012, respectively, and $1,204,000 and $645,000 for the nine months ended October 31, 2013 and 2012, respectively.
	The fair value of the stock options granted have been estimated at the date of grant using a Black-Scholes option pricing model. The option pricing model inputs assumptions such as expected term, expected volatility, and risk-free interest rate impact the fair value estimate. Further, the forfeiture rate impacts the amount of aggregate compensation. These assumptions are subjective and are generally derived from external (such as, risk-free rate of interest) and historical data (such as, volatility factor, expected term, and forfeiture rates). Future grants of equity awards accounted for as stock-based compensation could have a material impact on reported expenses depending upon the number, value and vesting period of future awards.
	The Company issues restricted stock awards in the form of Company common stock. The fair value of these awards is based on the market close price per share on the day of grant. The Company expenses the compensation cost of these awards as the restriction period lapses, which is typically a one-year service period to the Company.
Income Taxes	'
	Income Taxes
	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and for tax credit and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In assessing net deferred tax assets, the Company considers whether it is more likely than not that some or all of the deferred tax assets will not be realized. The Company establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.
	The Company provides for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether certain tax positions are more likely than not to be sustained upon examination by tax authorities. As of October 31, 2013, the Company believes it has appropriately accounted for any uncertain tax positions. As part of the Meta acquisition (discussed at Note C, below), the Company assumed a current liability for an uncertain tax position, and expects to settle this amount in fiscal 2013. The Company has a $152,000 reserve for uncertain tax positions and corresponding interest and penalties as of both October 31, 2013 and January 31, 2013, respectively.
Net Earnings (Loss) Per Common Share	'
	Net Earnings (Loss) Per Common Share
	The Company presents basic and diluted earnings per share (“EPS”) data for its common stock. Basic EPS is calculated by dividing the net income (loss) attributable to shareholders of the Company by the weighted average number of shares of common stock outstanding during the period. Diluted EPS is determined by adjusting the profit or loss attributable to shareholders and the weighted average number of shares of common stock outstanding adjusted for the effects of all dilutive potential common shares comprised of options granted, unvested restricted stocks, warrants and convertible preferred stock. Potential common stock equivalents that have been issued by the Company related to outstanding stock options, unvested restricted stock and warrants are determined using the treasury stock method, while potential common shares related to Series A Convertible Preferred Stock are determined using the “if converted” method.
	The Company's unvested restricted stock awards and Series A Convertible Preferred stock are considered participating securities under ASC 260, “Earnings Per Share”, which means the security may participate in undistributed earnings with common stock. The Company's unvested restricted stock awards are considered participating securities because they entitle holders to non-forfeitable rights to dividends or dividend equivalents during the vesting term. The holders of the Series A Preferred Stock would be entitled to share in dividends, on an as-converted basis, if the holders of common stock were to receive dividends, other than dividends in the form of common stock. In accordance with ASC 260, a company is required to use the two-class method when computing EPS when a company has a security that qualifies as a “participating security.” The two-class method is an earnings allocation formula that determines EPS for each class of common stock and participating security according to dividends declared (or accumulated) and participation rights in undistributed earnings. In determining the amount of net earnings to allocate to common stock holders, earnings are allocated to both common and participating securities based on their respective weighted-average shares outstanding for the period. Diluted EPS for the Company's common stock is computed using the more dilutive of the two-class method or the if-converted method.
	In accordance with ASC 260, securities are deemed to not be participating in losses if there is no obligation to fund such losses. For the three and nine months ended October 31, 2013, the unvested restricted stock awards and the Series A Preferred Stock were not deemed to be participating since there was a net loss from operations. For the three and nine months ended October 31, 2013, the effect of unvested restricted stock to the earnings per share calculation was immaterial. As of October 31, 2013, there were 3,249,995 shares of preferred stock outstanding, each share is convertible into one share of the Company's common stock. For the three and nine months ended October 31, 2013, the Series A Convertible Preferred Stock would have an anti-dilutive effect if included in diluted EPS and therefore, was not included in the calculation. As of October 31, 2013 and January 31, 2013, there were 29,698 and 137,327, respectively, unvested restricted shares of common stock outstanding. The unvested restricted shares at October 31, 2013 and January 31, 2013 were excluded from the calculation as their effect would have been antidilutive.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In February 2013, the Financial Accounting Standards Board ("FASB") issued an accounting standard update relating to improving the reporting of reclassifications out of accumulated other comprehensive income. The update would require an entity to report the effect of significant reclassifications out of accumulated other comprehensive income on the respective line items in net income if the amount being reclassified is required under GAAP to be reclassified in its entirety to net income. For other amounts that are not required under GAAP to be reclassified in their entirety to net income in the same reporting period, an entity is required to cross-reference other disclosures required under GAAP that provide additional detail about those amounts. The update is effective for reporting periods beginning after December 15, 2012. This standard did not have a material effect on the Company's consolidated financial position, results of operations, or cash flows.
	In July 2013, FASB issued an accounting standard update relating to the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. This update amends existing GAAP that required in certain cases, an unrecognized tax benefit, or portion of an unrecognized tax benefit, to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward when such items exist in the same taxing jurisdiction. The amendments in this update are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. Early adoption is permitted. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date, and retrospective application is permitted. We do not expect any impact from this update on our financial statements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Oct. 31, 2013
Accounting Policies [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted	'
	The following is the calculation of the basic and diluted net earnings (loss) per share of common stock:
		Three Months Ended
		31-Oct-13			31-Oct-12
	Net earnings (loss)	$	(6,232,418	)	$	2,399,637
	Less: deemed dividends on Series A Preferred Stock	(374,162		)	(139,133		)
	Net earnings (loss) attributable to common shareholders	$	(6,606,580	)	$	2,260,504
	Weighted average shares outstanding used in basic per common share computations	13,257,943			12,393,352
	Stock options and restricted stock	—			2,971,886
	Number of shares used in diluted per common share computation	13,257,943			15,365,238
	Basic net earnings (loss) per share of common stock	$	(0.50	)	$	0.18
	Diluted net earnings (loss) per share of common stock	$	(0.50	)	$	0.15
		Nine Months Ended
		31-Oct-13			31-Oct-12
	Net earnings (loss)	$	(9,770,468	)	$	2,427,995
	Less: deemed dividends on Series A Preferred Stock	(731,309		)	(139,133		)
	Net earnings (loss) attributable to common shareholders	$	(10,501,777	)	$	2,288,862
	Weighted average shares outstanding used in basic per common share computations	12,884,711			11,346,428
	Stock options and restricted stock	—			1,070,828
	Number of shares used in diluted per common share computation	12,884,711			12,417,256
	Basic net earnings (loss) per share of common stock	$	(0.82	)	$	0.2
	Diluted net earnings (loss) per share of common stock	$	(0.82	)	$	0.18

Acquisitions_Tables

Acquisitions (Tables)	9 Months Ended
	Oct. 31, 2013
Business Combinations [Abstract]	'
Purchase price allocation of assets and liabilities	'
	Under the acquisition method of accounting, the purchase price was allocated to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date as follows:
		August 16, 2012
	Assets purchased:
	Cash	$	1,126,000
	Accounts receivable	2,300,000
	Fixed assets	133,000
	Other assets	513,000
	Client relationships	4,464,000
	Internally developed software	3,646,000
	Trade name	1,588,000
	Supplier agreements	1,582,000
	Covenants not to compete	720,000
	Goodwill(1)	8,073,000
	Total assets purchased	$	24,145,000
	Liabilities assumed:
	Accounts payable and Accrued liabilities	1,259,000
	Deferred revenue obligation, net	3,494,000
	Deferred tax liability	4,602,000
	Net assets acquired	$	14,790,000
	Consideration:
	Company common stock	$	1,502,000
	Cash paid	13,288,000
	Total consideration	$	14,790,000
	_______________
	-1	Goodwill represents the excess of purchase price over the estimated fair value of net tangible and intangible assets acquired, which is not deductible for tax purposes.
	On October 25, 2013, the Company's wholly owned subsidiary, Streamline Health, Inc. ("Streamline"), entered into a Software License and Royalty Agreement (the “Royalty Agreement”) with Montefiore Medical Center ("Montefiore") pursuant to which it acquired an exclusive, worldwide 15-year license from Montefiore of its proprietary clinical analytics platform solution, Clinical Looking Glass ("CLG").  In addition, Montefiore assigned to Streamline the existing license agreement with a customer using CLG.  As consideration under the Royalty Agreement, Streamline paid Montefiore a one-time initial base royalty fee of $3,000,000, as well as on-going quarterly royalty amounts related to future sublicensing of CLG by Streamline.  Additionally, Streamline has committed that Montefiore will receive at least an additional $3,000,000 of on-going royalty payments within the first six and one-half years of the license term.
	The Montefiore agreements were accounted for as a business combination with the purchase price representing the $3,000,000 initial base royalty fee, plus the present value of the $3,000,000 on-going royalty payment commitment.The purchase price was allocated to the tangible and intangible assets acquired and liabilities assumed based on their estimate fair values as of the acquisition date as follows:
		October 25, 2013
	Assets purchased:
	License agreement	$	4,166,000
	Existing customer relationship	408,000
	Covenant not to compete	129,000
	Working capital	124,000
	Other assets	126,000
	Goodwill	272,000
	Total assets purchased	$	5,225,000
	Consideration:
	Cash paid	$	3,000,000
	Future royalty commitment	2,225,000
	Total consideration	$	5,225,000

Leases_Tables

Leases (Tables)	9 Months Ended
	Oct. 31, 2013
Leases [Abstract]	'
Schedule of future minimum lease payment	'
	Future minimum lease payments under non-cancelable operating leases for the next five fiscal years are as follows:
		Facilities		Equipment		Fiscal Year Totals
	2013 (three months remaining)	$	237,000	$	39,000	$	276,000
	2014	717,000		151,000		868,000
	2015	322,000		109,000		431,000
	2016	162,000		2,000		164,000
	2017	167,000		—		167,000
	2018	85,000		—		85,000
	Total	$	1,690,000	$	301,000	$	1,991,000

Debt_Tables

Debt (Tables)	9 Months Ended
	Oct. 31, 2013
Debt Disclosure [Abstract]	'
Summary of term loan and line of credit	'
	Outstanding principal balances on long-term debt consisted of the following at:
		31-Oct-13		31-Jan-13
	Senior term loan	$	3,750,000	$	4,688,000
	Subordinated term loan	9,000,000		9,000,000
	Total	12,750,000		13,688,000
	Less: Current portion	12,750,000		1,250,000
	Non-current portion of long-term debt	$	—	$	12,438,000
Schedule of future principal repayments of long-term debt	'
	Future principal repayments of long-term debt consisted of the following at October 31, 2013:
		Payments Due by Period
		2013		2014
	Senior term loan	$	312,000	$	3,438,000
	Subordinated term loan	—		9,000,000
	Total principal repayments	$	312,000	$	12,438,000

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Details) (USD $)

3 Months Ended

9 Months Ended

9 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

Oct. 31, 2013

Oct. 31, 2012

Oct. 31, 2013

Oct. 31, 2012

Jan. 31, 2013

Oct. 31, 2013

Oct. 31, 2012

Oct. 31, 2013

Oct. 31, 2013

Jan. 31, 2013

Oct. 31, 2013

Oct. 31, 2012

Oct. 31, 2013

Oct. 31, 2012

Oct. 31, 2013

Oct. 31, 2012

Employee Severance

Employee Severance

Convertible Preferred Stock

Restricted Stock

Restricted Stock

Stock Options

Stock Options

Stock Options

Stock Options

Warrant

Warrant

Summary Of Significant Accounting Policies

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred professional costs

$368,000

'

$368,000

'

$201,000

'

'

'

'

'

'

'

'

'

'

'

Accumulated amortization of professional expenses

85,000

'

85,000

'

35,000

'

'

'

'

'

'

'

'

'

'

'

Severance expenses

0

207,000

380,000

277,000

'

'

'

'

'

'

'

'

'

'

'

'

Accrued severances

'

'

'

'

'

13,000

548,000

'

'

'

'

'

'

'

'

'

Share-based compensation expense

378,000

245,000

1,203,919

645,407

'

'

'

'

'

'

'

'

'

'

'

'

Reserves for uncertain tax positions and corresponding interest and penalties

$152,000

'

$152,000

'

$152,000

'

'

'

'

'

'

'

'

'

'

'

Antidilutive securities

'

'

'

'

'

'

'

3,249,995

29,698

137,327

2,549,178

2,310,218

2,562,317

2,585,079

1,400,000

0

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Earnings Per Share (Details) (USD $)	3 Months Ended		9 Months Ended
	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2013	Oct. 31, 2012
Accounting Policies [Abstract]	'	'	'	'
Net earnings (loss)	($6,232,418)	$2,399,637	($9,770,468)	$2,427,995
Less: deemed dividends on Series A Preferred Shares	-374,162	-139,133	-731,309	-139,133
Net earnings (loss) attributable to common shareholders	($6,606,580)	$2,260,504	($10,501,777)	$2,288,862
Weighted average shares outstanding used in basic per common share computations	13,257,943	12,393,352	12,884,711	11,346,428
Stock options and restricted stock	0	2,971,886	0	1,070,828
Number of shares used in diluted per common share computation	13,257,943	15,365,238	12,884,711	12,417,256
Basic net earnings (loss) per common share (in dollars per share)	($0.50)	$0.18	($0.82)	$0.20
Diluted net earnings (loss) per common share (in dollars per share)	($0.50)	$0.15	($0.82)	$0.18

Acquisitions_Additional_Inform

Acquisitions - Additional Information (Details) (USD $)	9 Months Ended	12 Months Ended			9 Months Ended		0 Months Ended		0 Months Ended
	Oct. 31, 2013	Jan. 31, 2014	Jan. 31, 2013	Dec. 07, 2011	Oct. 31, 2013	Jan. 31, 2013	Aug. 16, 2012	Oct. 31, 2013	Oct. 25, 2013	Oct. 25, 2013
					Interpoint Partners, LLC	Interpoint Partners, LLC	Meta	Meta	Montefiore	Montefiore
										Forecast
Acquisitions (Textual) [Abstract]	'	'	'	'	'	'	'	'	'	'
Current estimated value of contingent earn-out provision	$5,460,000	'	$1,320,000	'	$5,460,000	$1,320,000	'	'	'	'
Earn-out obligation to be paid in cash	'	'	'	'	1,300,000	'	'	'	'	'
Issuance of common shares	'	'	'	'	400,000	'	393,086	'	'	'
Expected Term of Note	'	'3 years	'	'	'	'	'	'	'	'
Face amount of debt	'	'	'	4,120,000	'	'	'	'	'	'
Debt Instrument, Interest Rate, Stated Percentage	8.00%	'	'	'	'	'	'	'	'	'
Completion date of acquisition	'	'	'	'	'	'	16-Aug-12	'	'	'
Purchase price	'	'	'	'	'	'	14,790,000	'	'	'
Cash paid	'	'	'	'	'	'	13,288,000	'	'	'
Common stock price per share (USD per share)	'	'	'	'	'	'	$4.07	'	'	'
Fair value of common stock (USD per share)	'	'	'	'	'	'	$3.82	'	'	'
Working capital settlement, recorded receivables	'	'	'	'	'	'	'	378,000	'	'
License Agreement, Term	'15 years	'	'	'	'	'	'	'	'	'
Cash paid	'	'	'	'	'	'	'	'	3,000,000	'
Future royalty commitment	'	'	'	'	'	'	'	'	$2,225,000	$3,000,000

Acquisitions_Meta_Health_Techn

Acquisitions - Meta Health Technology Purchase Price Allocation of Assets and Liabilities (Details) (Meta [Member], USD $)	Aug. 16, 2012
In Thousands, unless otherwise specified
Meta [Member]	'
Assets purchased:	'
Cash	$1,126
Accounts receivable	2,300
Fixed assets	133
Other assets	513
Client relationships	4,464
Internally developed software	3,646
Trade name	1,588
Supplier agreements	1,582
Covenant not to compete	720
Goodwill	8,073	[1]
Total assets purchased	24,145
Liabilities assumed:	'
Accounts payable and accrued liabilities	1,259
Deferred revenue obligation, net	3,494
Deferred tax liability	4,602
Net assets acquired	14,790
Consideration:	'
Company common stock	1,502
Cash paid	13,288
Total consideration	$14,790
[1]	Goodwill represents the excess of purchase price over the estimated fair value of net tangible and intangible assets acquired, which is not deductible for tax purposes.

Acquisitions_Business_Combinat

Acquisitions - Business Combination (Details) (USD $)	Oct. 31, 2013	Jan. 31, 2013	Oct. 25, 2013
			Montefiore
Assets purchased:	'	'	'
License agreement	'	'	$4,166,000
Existing customer relationship	'	'	408,000
Covenant not to compete	'	'	129,000
Working capital	'	'	124,000
Other assets	'	'	126,000
Goodwill	12,344,199	12,133,304	272,000
Total assets purchased	'	'	5,225,000
Consideration:	'	'	'
Cash paid	'	'	3,000,000
Future royalty commitment	'	'	2,225,000
Total consideration	'	'	$5,225,000

Derivative_Liabilities_Additio

Derivative Liabilities - Additional Information (Details) (USD $)

1 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

3 Months Ended

Aug. 31, 2012

Oct. 31, 2013

Oct. 31, 2013

Aug. 16, 2012

Oct. 31, 2013

Oct. 31, 2013

Oct. 31, 2013

Oct. 31, 2013

Apr. 30, 2013

Oct. 31, 2012

Oct. 31, 2013

Jan. 31, 2013

Valuation of Common Stock Warrants

Valuation of Common Stock Warrants

Valuation of Common Stock Warrants

Valuation of Common Stock Warrants

Other Income

Estimate of Fair Value

Estimate of Fair Value

Estimate of Fair Value

Deferred Financing Costs

Dividend Declared

Series A Preferred Stock

Additional paid in capital

Valuation of Common Stock Warrants

Common Stock Warrant

Common Stock Warrant

Derivative Liabilities [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Warrants exercisable (in shares)

'

'

'

1,200,000

'

'

'

'

'

'

'

'

Exercise price (USD per share)

'

'

'

3.99

'

'

'

'

'

'

'

'

Net of transaction costs, allocated to the warrants

$1,425,000

'

'

'

'

'

'

'

'

'

'

'

Warrant liability at fair value

'

'

'

'

'

'

'

'

'

4,139,000

'

'

Fair value of warrants

'

'

'

'

'

'

'

'

'

'

6,393,000

2,083,000

Annual volatility

'

'

58.77%

'

'

'

'

'

'

'

'

'

Risk-free rate

'

'

1.00%

'

'

'

'

'

'

'

'

'

Dividend yield

'

'

0.00%

'

'

'

'

'

'

'

'

'

Expected life

'

'

'4 years 3 months 18 days

'

'

'

'

'

'

'

'

'

Immaterial correction for valuation of common stock warrants

'

$188,145

'

'

$51,000

$150,000

$7,000

$602,000

$19,000

'

'

'

Leases_Future_Minimum_Lease_Pa

Leases - Future Minimum Lease Payments (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2013	Oct. 31, 2012
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]	'	'	'	'
2013 (three months remaining)	$276	'	$276	'
2014	868	'	868	'
2015	431	'	431	'
2016	164	'	164	'
2017	167	'	167	'
2018	85	'	85	'
Total	1,991	'	1,991	'
Rent expense	324	256	877	702
Facilities	'	'	'	'
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]	'	'	'	'
2013 (three months remaining)	237	'	237	'
2014	717	'	717	'
2015	322	'	322	'
2016	162	'	162	'
2017	167	'	167	'
2018	85	'	85	'
Total	1,690	'	1,690	'
Equipment	'	'	'	'
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]	'	'	'	'
2013 (three months remaining)	39	'	39	'
2014	151	'	151	'
2015	109	'	109	'
2016	2	'	2	'
2017	0	'	0	'
2018	0	'	0	'
Total	$301	'	$301	'

Debt_Additional_Information_De

Debt - Additional Information (Details) (USD $)

0 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

0 Months Ended

Aug. 16, 2012

Oct. 31, 2013

Oct. 31, 2012

Jan. 31, 2013

Dec. 07, 2011

Aug. 16, 2012

Oct. 31, 2013

Aug. 16, 2012

Oct. 31, 2013

Oct. 31, 2013

Jan. 31, 2013

Dec. 13, 2013

Dec. 13, 2013

Dec. 13, 2013

Nov. 20, 2013

Term loan

Revolving Credit Facility

Subordinated Debt

Subordinated Debt

Interpoint Partners LLC

Interpoint Partners LLC

Subsequent Event

Subsequent Event

Subsequent Event

Unsecured Subordinated Notes Due November, 2016

Revolving Credit Facility

Subordinated Debt

Senior Notes

Subsequent Event

Subordinated Debt

Debt Instruments [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Face amount of debt

'

'

'

'

$4,120,000

'

'

'

'

'

'

'

'

$8,500,000

$900,000

Revolving line of credit

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Senior term loan

5,000,000

'

'

'

'

'

'

9,000,000

'

'

'

'

'

'

'

Subordinated credit agreement bank provided, term loan maturing

'

'

'

'

'

4,120,000

0

'

'

'

'

'

'

'

'

Success fee included in the previous subordinated term loan

'

'

'

'

'

700,000

'

'

'

'

'

'

'

'

'

Success fees accruals

233,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Commitment fee in connection with the term loan

'

'

'

'

'

75,000

3,000

'

'

'

'

'

'

'

'

Internal rate of return required by lender

'

'

'

'

'

'

'

'

1700.00%

'

'

'

'

'

'

Installment payments due

'

'

'

'

'

'

'

'

'

'

'

'

'

101,000

'

LIBOR in effect

'

0.17%

'

'

'

'

'

'

'

'

'

'

'

'

'

Borrowing under the revolving loan bears interest at a rate equal to LIBOR plus

'

'

'

'

'

'

'

'

'

'

'

3.50%

10.00%

4.75%

'

Commitment fee percentage

'

'

'

'

'

'

'

'

'

'

'

0.40%

'

'

'

Fee amount

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

Debt covenant, minimum adjusted EBITDA, beginning July 31, 2013

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

Debt Instrument, Annual Principal Payment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

Accrues interest per annum rate

'

8.00%

'

'

'

'

'

'

'

'

'

'

'

'

8.00%

Maintain a fixed charge coverage ratio for fiscal quarter ending

'

1.2

'

'

'

'

'

'

'

'

'

'

'

'

'

Consolidated basis, maintain ratio of funded debt to adjusted EBITDA

'

3.5

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Covenant, Senior Funded Debt to EBITDA Ratio, Maximum

'

2.5

'

'

'

'

'

'

'

'

'

'

'

'

'

Asset purchase agreement

'

3,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Earn-out Restriction Conversion

'

'1 year

'

'

'

'

'

'

'

'

'

'

'

'

'

Earn-out obligation to be paid in cash

'

'

'

'

'

'

'

'

'

1,300,000

'

'

'

'

'

Issuance of common shares

'

'

'

'

'

'

'

'

'

400,000

'

'

'

'

'

Current estimated value of contingent earn-out provision

'

5,460,000

'

1,320,000

'

'

'

'

'

5,460,000

1,320,000

'

'

'

'

Valuation adjustment for contingent earn-out

'

$4,140,441

$86,839

'

'

'

'

'

'

'

'

'

'

'

'

Debt_Summary_of_Term_Loan_and_

Debt - Summary of Term Loan and Line of Credit (Details) (USD $)	Oct. 31, 2013	Jan. 31, 2013
In Thousands, unless otherwise specified
Debt Instrument	'	'
Total Debt	$12,750	$13,688
Less: Current portion	12,750	1,250
Non-current portion of long-term debt	0	12,438
Senior Notes	'	'
Debt Instrument	'	'
Total Debt	3,750	4,688
Senior Subordinated Notes	'	'
Debt Instrument	'	'
Total Debt	$9,000	$9,000

Debt_Schedule_of_Future_Princi

Debt - Schedule of Future Principal Repayments of Long-Term Debt (Details) (USD $)	Oct. 31, 2013
In Thousands, unless otherwise specified
Debt Instrument	'
Payments Due by 2013	$312
Payments Due by 2014	12,438
Senior Notes	'
Debt Instrument	'
Payments Due by 2013	312
Payments Due by 2014	3,438
Senior Subordinated Notes	'
Debt Instrument	'
Payments Due by 2013	0
Payments Due by 2014	$9,000

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended		9 Months Ended
	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2013	Oct. 31, 2012
Federal tax provisions	'	'	$126,000	($3,565,000)
State and local tax provisions	'	'	33,000	30,000
Income tax expense	-4,680	-3,552,879	158,944	-3,519,879
Interpoint Partners LLC | Restatement Adjustment | Business Combination Deferred Tax Adjustment	'	'	'	'
Income tax expense	$100,000	'	'	'

Subsequent_Events_Details

Subsequent Events (Details) (Subsequent Event, USD $)	0 Months Ended			12 Months Ended	0 Months Ended
Share data in Thousands, except Per Share data, unless otherwise specified	Nov. 22, 2013	Nov. 14, 2013	Nov. 14, 2013	Jun. 30, 2013	Nov. 14, 2013	Nov. 22, 2013
		entity	Aquiree One	Aquiree One	Aquiree Two	Common stock
Subsequent Event [Line Items]	'	'	'	'	'	'
Stock issued during period, new issues (in shares)	'	'	'	'	'	3,450
Number of businesses to be acquired	'	2	'	'	'	'
Revenues	'	'	'	$3.90	'	'
Recurring revenues	'	'	'	3,200,000	'	'
Expected consideration	'	'	6.5	'	13,750,000	'
Shares Issued, Price Per Share	'	'	'	'	'	$6.50
Proceeds from Issuance of Common Stock, Net	$20,345,000	'	'	'	'	'

Stockholers_Equity_Details

Stockholers Equity (Details) (USD $)	3 Months Ended	0 Months Ended
In Thousands, except Share data, unless otherwise specified	Oct. 31, 2013	Nov. 22, 2013	Nov. 22, 2013
	Series A Preferred Stock	Subsequent Event	Subsequent Event
			Common Stock [Member]
Class of Stock [Line Items]	'	'	'
Preferred stock, shares issued	750,000	'	'
Adjustments to Additional Paid in Capital, Other	$919	'	'
Preferred Stock, Shares Outstanding	3,249,995	'	'
Stock issued during period, new issues (in shares)	'	'	3,450,000
Shares Issued, Overall Option Exercised	'	'	450,000
Shares Issued, Price Per Share	'	'	$6.50
Proceeds from Issuance of Common Stock, Net	'	20,345	'
Payments of Stock Issuance Costs	'	'	$400